Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenstr öm Macroglobulinemia Treated With First-Line BTK Inhibitors

Conditions:   Chronic Lymphocytic Leukemia (CLL);   Waldenstrom Macroglobulinemia (WM) Intervention:   Drug: Shingrix vaccine Sponsor:   University of Rochester Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials